Procoagulant Microparticles: New Insights and Opportunities in Pregnancy Loss?

Summary

In recent years, prothrombotic states have been not only associated with an increased risk of venous thrombosis, but also with pregnancy complications. In particular there is good evidence linking antiphospholipid antibody syndrome, which is associated with increased thrombin generation (1), to recurrent miscarriage. The importance of procoagulant changes in the pathophysiology of recurrent miscarriage is emphasised by the fact that treatment with heparin and low dose aspirin will substantially improve the likelihood of a successful pregnancy (2). Essentially, this is the only successful medical intervention in the treatment of miscarriage. There are also data now accumulating that link congenital thrombophilia to pregnancy complications such as miscarriage, pre-eclampsia, intra-uterine growth restriction, abruption and intrauterine death (3, 4). Furthermore, recent data have shown that acquired changes in the coagulation system, such as the acquired activated protein C resistance of pregnancy is also associated with an increased risk of pre-eclampsia (5). These data collectively suggest that procoagulant changes in general, rather than congenital or acquired thrombophilia in particular are associated with the development of pregnancy complications including fetal loss. However, in the majority of cases of fetal loss no cause is found and we cannot easily link these events to a procoagulant problem in the mother. In this issue of the Thrombosis and Haemostasis, Laude et al. (6) report, for the first time, the association between circulating procoagulant microparticles and pregnancy loss so providing a new insight into potential mechanisms.

• References

• 1 Vincent T, Rai R, Regan L, Cohen H. Increased thrombin generation in women with recurrent miscarriage. Lancet 1998; 352: 116.
• 2 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. BMJ 1997; 314: 253-7.
• 3 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.
• 4 Kupferminc MJ, Eldor A, Steinman N. et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999; 341: 9-13.
• 5 Clark P, Sattar N, Walker ID, Greer IA. The Glasgow outcome, APCR and lipid (GOAL) pregnancy study: significance of pregnancy associated activated protein C resistance. Thromb Haemost 2001; 85: 30-5.
• 6 Laude I, Rongieres-Bertrand C, Boyer-Neumann C. et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001; 85: 18-21.
• 7 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-88.
• 8 Warkentin TE, Hayward CPM, Boshkov LK, Santos AV. et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
• 9 Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost 1996; 75: 427-31.
• 10 Hugel B, Socie G, Toti F, Gluckman E. et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451-6.
• 11 Mallat Z, Benamer H, Hugel B, Benessiano J. et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-8.
• 12 Giesen PL, Rauch U, Borhmann B, Kling D. et al. Blood-borne tissue factor: another view of thrombosis. Med Sci 1999; 96: 2311-5.
• 13 Gilbert GE, Sims PJ, Widemer T, Furie B. et al. Platelet-derived microparticles express high affinity receptors for Factor VIII. J Biol Chem 1991; 266: 17261-8.
• 14 Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
• 15 Barry OP, Practico D, Lawson JA, Fitzgerald GA. Transcellular activation of platelets and endothelial cels by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-27.
• 16 Albanese J, Meterissian S, Kontogiannea M. et al. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood 1998; 91: 3862-74.
• 17 Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161: 4382-7.
• 18 Sugimura M, Kobayashi T, Shu F. et al. Annexin V inhibits phosphatidylserine-induced intrauterine growth restriction in mice. Placenta 1999; 20: 555-60.
• 19 Rand JH, Wu X-X, Andree HAM. et al. Pregnancy loss in the antiphospholipid-antibody syndrome – a possible thrombogenic mechanism. N Eng J Med 1997; 337: 154-60.
• 20 Keularts IM, Beguin S, de Swaan C. et al. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb Haemost 1998; 80: 370-1.